Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

被引：6

作者：

Reich-Slotky, Ronit ^{[1
]}

Al-Mulla, Naima ^{[2
]}

Hafez, Rania ^{[3
]}

Segovia-Gomez, Javier ^{[4
]}

Goel, Ruchika ^{[5
,6
]}

Mayer, Sebastian ^{[7
]}

Phillips, Adrienne ^{[7
]}

Shore, Tsiporah B. ^{[7
]}

Hsu Jing-Mei ^{[7
]}

Hsu, Yen-Michael Sheng ^{[7
]}

Vasovic, Ljiljana V. ^{[7
]}

Cushing, Melissa M. ^{[7
]}

Gergis, Usama ^{[7
]}

机构：

[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[2] Hamad Med Corp, Doha, Qatar

[3] Assiut Univ, Sch Med, Assiute, Egypt

[4] Cent Mil Hosp Bogota, Bogota, Colombia

[5] Johns Hopkins Univ, Dept Pathol, Div Transfus Med, Baltimore, MD USA

[6] Simmons Canc Inst, SIU Sch Med, Springfield, IL USA

[7] Weill Cornell Med Coll, Pathol, New York Presbyterian Hosp, New York, NY USA

来源：

LEUKEMIA & LYMPHOMA | 2020年 / 61卷 / 12期

关键词：

PGF; delayed hematopoietic recovery; poor graft function; CORD BLOOD TRANSPLANTATION; BONE-MARROW; ABO INCOMPATIBILITY; PLATELET RECOVERY; HOST-DISEASE; DONOR; HLA; IMPACT; OUTCOMES; APLASIA;

D O I：

10.1080/10428194.2020.1789622

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PGF implies persistent cytopenia in the presence of predominant donor chimerism. We examined contributors to PGF in 104 HCT recipients who survived >= 100 days without relapse or major complications. Surrogate parameters for PGF were: Hg <10 g/dl, RBC transfusion dependence, platelet count <20 x 10(9)/L or ANC < 0.5 x 10(9)/L. All patients received T cell depletion with alemtuzumab or ATG. The 2-year OS and PFS probabilities were 66%, 95%CI (56 - 75%) and 51%, 95%CI (41-60%) respectively. Fifty-four patients (52%) met one or more PGF criteria. There was significant association between major ABO incompatibility and platelet <20 x 109/L (OR = 4.7, 95%CI 1.05-21.26,p = .043), acute GVHD and Hg <10 g/dl (OR 3.7, 95%CI 1.4-9.6,p = .005) and CMV viremia and ANC < 0.5 x 10(9)/L (OR 3.0, 95% CI 1.0, 8.7,p = .043). NRM was significantly higher in the PGF group compared to patients with adequate graft function (45.5% vs 16.7%,p = .014).

引用

页码：2894 / 2899

页数：6

共 37 条

[1]

ANASETTI C, 1989, BLOOD, V73, P1054

[2]

Bar BMAM, 1995, BONE MARROW TRANSPL, V16, P793

[3] How I treat: the selection and acquisition of unrelated cord blood grafts [J].